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ABSTRACT
Background. As the real clinical signiﬁcance of carcino-
embryonic antigen (CEA) and carbohydrate antigen 19.9
(CA19.9) evolution during preoperative chemotherapy for
colorectal liver metastases (CLM) is still unknown, we
explored the correlation between biological and radiolog-
ical response to chemotherapy, and their comparative
impact on outcome after hepatectomy.
Methods. All patients resected for CLM at our hospital
between 1990 and 2004 with the following eligibility cri-
teria were included in the study: (1) preoperative
chemotherapy, (2) complete resection of CLM, (3) no
extrahepatic disease, and (4) elevated baseline tumor
marker values. A 20% change of tumor marker levels while
on chemotherapy was used to deﬁne biological response
(decrease) or progression (increase). Correlation between
biological and radiological response at computed tomog-
raphy (CT) scan, and their impact on overall survival (OS)
and progression-free survival (PFS) after hepatectomy
were determined.
Results. Among 119 of 695 consecutive patients resected
for CLM who fulﬁlled the inclusion criteria, serial CEA and
CA19.9 were available in 113 and 68 patients, respectively.
Of patients with radiological response or stabilization, 94%
had similar biological evolution for CEA and 91% for
CA19.9. In patients with radiological progression, similar
biological evolution was observed in 95% of cases for CEA
and in 64% for CA19.9. On multivariate analysis, radiolog-
ical response (but not biological evolution) independently
predicted OS. However, progression of CA19.9, but not
radiological response, was an independent predictor of PFS.
Conclusions. In patients with CLM and elevated tumor
markers, biological response is as accurate as CT imaging
to assess ‘‘clinical’’ response to chemotherapy. With
regards to PFS, CA19.9 evolution has even better prog-
nostic value than does radiological response. Assessment
of tumor markers could be sufﬁcient to evaluate chemo-
therapy response in a nonsurgical setting, limiting the need
of repeat imaging.
Hepatic resection is still considered the most effective
treatment for patients with colorectal liver metastases
(CLM).
1 Unfortunately, only 10–20% of patients are
directly amenable to surgery.
2 In the remaining patients,
complete metastatic resection would result in a too small
volume of remnant functional liver parenchyma. However,
due to major improvements in chemotherapy regimens, 13–
54% of initially unresectable patients can now be switched
to resectability.
3–9 Besides this, systemic chemotherapy is
increasingly being used in a neoadjuvant setting (i.e., in
initially resectable patients) with the aim of facilitating
hepatic resection and improving long-term outcome.
10,11
To determine the efﬁcacy of preoperative chemother-
apy, computed tomography (CT) is the gold standard.
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Furthermore, best surgical candidates can be identiﬁed, as
disease progression while on preoperative chemotherapy is
associated with poor outcome.
12 Besides CT imaging, car-
cinoembryonic antigen (CEA) and/or carbohydrate antigen
19.9 (CA19.9) are widely used to monitor patients while on
chemotherapy. Although the prognostic signiﬁcance of
increased preoperative CEA and CA19.9 levels has been
wellestablishedinlargeseries,clinicalsigniﬁcanceoftumor
marker evolutionregardingcorrelation with imagingstudies
and impact on long-term outcome is still unclear.
13–17 To
date, only limited data is available suggesting a correlation
between CEA evolution and chemotherapy response at CT
imaginginpatientswithadvancedcolorectalcancer.
18–20As
patient selection often was not well deﬁned, data interpre-
tation remains difﬁcult. Recently, the American Society of
Clinical Oncology recommended CEA as the marker of
choice for monitoring metastatic colorectal cancer during
systemic therapy.
21 On the contrary, insufﬁcient data was
available to recommend use of CA19.9 for evaluating
treatment results in metastatic colorectal cancer patients.
21
The aim of the present study is to explore the correlation
between biological and radiological response following
preoperative chemotherapy, and their comparative impact
on long-term outcome, for both CEA and CA19.9, in a
well-deﬁned population of patients with isolated CLM,
scheduled for hepatectomy.
PATIENTS AND METHODS
Patients
All consecutive patients treated for CLM at our hospital
between January 1990 and January 2004 with the following
eligibility criteria were entered in the study: (1) treated by
hepatectomy preceded by chemotherapy, (2) data for at
least one tumor marker available, (3) primary tumor
resected at least 6 months before last preoperative che-
motherapy, (4) no extrahepatic disease diagnosed before or
during hepatectomy, (5) CT reports before and after pre-
operative chemotherapy available, and (6) elevated tumor
marker levels at baseline measurement (i.e., before pre-
operative chemotherapy). Patients were selected from our
prospectively collected institutional database, and the
medical record of each patient was reviewed.
Preoperative Management
Before hepatectomy, all patients were treated with at
least one line of chemotherapy, either to achieve resect-
ability in patients with initially unresectable CLM (i.e.,
inability to resect the total amount of CLM while leaving at
least 30% future remnant liver volume) or in a neoadjuvant
setting in patients with synchronous (i.e., diagnosed before,
during or within 3 months after colorectal resection) or
marginally resectable CLM (i.e., multinodular bilateral
CLM).
In every patient, serum CEA and/or CA19.9 levels were
routinely measured before, during, and after preoperative
chemotherapy at our institution. Tumor markers were
measured in fresh sera using Architect I2000SR CMIA
technology (Abbott Diagnostics, Abbott Park, IL). Tumor
marker levels\5 ng/ml for CEA and\37 U/ml for
CA19.9 were considered normal.
Clinical response at CT imaging during chemotherapy
was routinely evaluated every 2 months in a multidisci-
plinary staff meeting, including surgeons, medical
oncologists, and radiologists. For every patient, the CT
scan was reviewed by an expert radiologist blinded to
tumor marker evolution, and type of radiological response
after the last preoperative chemotherapy line was deter-
mined according to the Response Evaluation Criteria in
Solid Tumors (RECIST).
22
Hepatic Resection
All patients underwent hepatic resection with curative
intent, after exploration by intraoperative ultrasound. If
needed to allow resection, preoperative portal vein emboli-
zation was performed.
23 Hepatic resections were classiﬁed
as major (C3 segments) or limited (\3 segments).
24,25
Postoperative Follow-Up
Postoperatively, all patients were followed up regularly,
starting 1 month after the operation and then every
4 months, consisting of clinical examination, serum tumor
markers, abdominal ultrasound, and thoracoabdominal
imaging. To reduce risk of recurrence, adjuvant chemo-
therapy was routinely recommended. If intra- and/or
extrahepatic disease recurrence occurred which could be
resected curatively, repeat resection was performed.
26
Statistical Considerations
Mean tumor marker levels before and after the last
preoperative chemotherapy were compared by paired-
samples t test. To analyze the clinical signiﬁcance of tumor
marker evolution, a cutoff point of 20% change in tumor
marker level after chemotherapy was chosen, as best
agreement between radiological and biological response
was observed when using this cutoff point, as assessed by
the Cohen kappa test. A decrease of tumor marker level of
20% or more was deﬁned as biological response. Likewise,
an increase of tumor marker level of 20% or more was
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tumor marker level by less than 20% was considered as
biological stabilization. To analyze the correlation between
biological and radiological response after chemotherapy, as
well as the impact of tumor marker evolution on survival,
response and stabilization were grouped together (positive
cases) and compared with progression (negative cases).
Sensitivity, speciﬁcity, positive predictive value (PPV),
and negative predictive value (NPV) of tumor marker
evolution were calculated, considering radiological
response at CT imaging as reference standard.
Overall and progression-free survival curves were cal-
culated by Kaplan–Meier method, and survivals of different
groups were compared using log-rank tests. Survival rates
were calculated from time of hepatectomy. Univariate
associations between study variables (including patient,
primary tumor, initial CLM, chemotherapy, and hepatec-
tomy characteristics) and both overall and progression-free
survivalweredeterminedbylog-ranktestPvalue B0.05.To
identify independent predictors of overall and progression-
free survival, factors with univariate P value B0.10 were
entered in a multivariate Cox proportional hazard model. P
value B0.05 was considered statistically signiﬁcant. All
statistical analyses were performed by using SPSS version
13.0 (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Between 1990 and 2004, 695 patients underwent hepatic
resection for CLM at our hospital. Of these, 119 patients
(17%) fulﬁlled the inclusion criteria and were subsequently
enrolled in the study (Fig. 1). The study population con-
sisted of 79 men (66%) and 40 women (34%), and mean
age was 61 years (Table 1). In 95 patients (80%), the pri-
mary tumor was located in the colon. Forty-one patients
(34%) presented with CLM synchronous to the primary
colorectal malignancy. It concerned only one liver metas-
tasis in 34 patients (30%), and metastases were initially
unresectable in 55 patients (46%).
Preoperative Chemotherapy
Before hepatic resection, all patients were treated by at
least one line of chemotherapy. A median number of 1 line
(range 1–5) and a median number of 7 cycles (range 2–33)
of systemic chemotherapy were administered. Radiological
response of CLM after chemotherapy was observed in 72
patients (60%), stabilization in 28 (24%), and disease
progression in 19 (16%). Chemotherapy details are indi-
cated in Table 2.
Tumor Marker Evolution
Data to determine the biological response were avail-
able in 113 cases for CEA and in 68 cases for CA19.9
Paul Brousse Hospital (1990–2004)
total number of resected patients
n = 695 (100%)
Remaining study population
n = 119 (17%)
Patients excluded
n = 576 (83%):
No preoperative
chemotherapy: n = 106
Colorectal resection < 6
months before last pre-HR
chemotherapy line: n = 173
Concomitant extrahepatic
disease: n = 106
Normal tumor marker
levels: n = 85
Stabilization at CT-scan
n = 28 (4%)
Analyzed tumor marker
(n = 28)
Both: n = 16
CEA: n = 10
CA19.9: n = 2
Progression at CT-scan
n = 19 (3%)
Analyzed tumor marker
(n = 19)
Both: n = 11
CEA: n = 8
CA19.9: n = 0
Response at CT-scan
n = 72 (10%)
Analyzed tumor marker
(n = 72)
Both: n = 35
CEA: n = 33
CA19.9: n = 4
FIG. 1 Flowchart of study population. HR hepatic resection, CT
computed tomography, CEA carcinoembryonic antigen, CA carbohy-
drate antigen
TABLE 1 Patient and tumoral characteristics
Characteristics Total study population (N = 119)
Patients
Mean age at HR, years ± SD 61 ± 10
Male/female 79 (66%)/40 (34%)
Primary tumor
Colon/rectum 95 (80%)/24 (20%)
T classiﬁcation
1 2 (2%)
2 7 (8%)
3 41 (49%)
4 33 (40%)
N classiﬁcation
0 33 (39%)
1 28 (33%)
2 24 (28%)
Liver metastases at initial diagnosis
Synchronous/metachronous
a 41 (34%)/78 (66%)
Number of CLM
1 34 (30%)
2–3 44 (38%)
[3 37 (32%)
Mean maximum size, mm ± SD 46 ± 32
Unilateral/bilateral 61 (52%)/57 (48%)
Initial unresectability 55 (46%)
HR hepatic resection, SD standard deviation, CLM colorectal liver
metastases
a Synchronous = diagnosed before, during, or within 3 months after
colorectal resection
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therapy within the total study population are shown in
Table 2.
The mean CEA level after chemotherapy in patients
with radiological response of CLM was signiﬁcantly lower
compared with the mean value before preoperative che-
motherapy (Fig. 2a). If either stabilization or progression
of CLM was observed following chemotherapy, mean CEA
level did not signiﬁcantly differ from that determined
before starting preoperative chemotherapy (Fig. 2b, c).
When using a cutoff point of 20% to deﬁne biological
response, agreement between biological (CEA) and radio-
logical response was observed in 80% of cases (90/113),
with a kappa value of 0.62 [95% conﬁdence interval (CI):
0.49–0.76] (Table 3). Sensitivity was 94% (95% CI: 89–
99%), speciﬁcity was 95% (95% CI: 85–105%), and PPV
and NPV were 99% (95% CI: 97–101%) and 75% (95%
CI: 58–92%), respectively.
TABLE 2 Operative features
5-FU 5-ﬂuorouracil, LV
leucovorin, CT computed
tomography, CEA
carcinoembryonic antigen, CA
carbohydrate antigen, PVE
portal vein embolization, CLM
colorectal liver metastases, SD
standard deviation
a According to RECIST
criteria
22
b Cutoff point 20%
c R0: complete surgical
resection with a negative
surgical margin at
histopathology; R1: invaded
surgical margins according to
the pathologist; R2:
macroscopic tumor remnant
intraoperatively
d Hepatic complications
considered were: biliary leak/
bilioma, hemorrhage, infected
collection, noninfected
collection, and transient liver
insufﬁciency
e General complications
considered were: pulmonary,
cardiovascular, urinary tract,
infectious (other than local
hepatic), and iatrogenic
complications
Feature Total study population (N = 119)
Preoperative chemotherapy 119 (100%)
Total no. of lines
1 87 (73%)
[1 32 (27%)
Total no. of cycles
\6 27 (24%)
C6 85 (76%)
Regimen last preoperative line
5-FU LV 32 (27%)
5-FU LV oxaliplatin 61 (51%)
5-FU LV irinotecan 18 (15%)
Other 8 (7%)
Chronomodulated delivery 59 (50%)
Clinical response at CT scan
a
Response 72 (60%)
Stabilization 28 (24%)
Progression 19 (16%)
Change in CEA level after chemotherapy (N = 113)
b
Response 75 (66%)
Stabilization 14 (12%)
Progression 24 (21%)
Change in CA19.9 level after chemotherapy (N = 68)
b
Response 48 (71%)
Stabilization 8 (12%)
Progression 12 (18%)
Hepatectomy
PVE 14 (12%)
Major hepatectomy (C3 segments) 62 (52%)
Mean no. of CLM at histopathology ± SD 3 ± 3
Mean maximum size of CLM at histopathology, mm ± SD 44 ± 36
Surgical margin status
c
R0 71 (60%)
R1 43 (36%)
R2 4 (3%)
Postoperative mortality (B2 months) 1 (1%)
Postoperative complications 43 patients (36%)
Hepatic
d 31 (26%)
General
e 20 (17%)
Postoperative chemotherapy 105 (88%)
Tumor Marker Evolution in CLM Patients 1013Although not statistically different, observed changes in
mean CA19.9 levels measured before and after preopera-
tive chemotherapy were in accordance with their
corresponding radiological response categories, as dem-
onstrated in Fig. 3a–c. Biological (CA19.9) and radio-
logical response correlated favorably in 72% of cases (49/
68), with a kappa value of 0.46 (95% CI: 0.25–0.59)
(Table 3). Sensitivity was 91% (95% CI: 84–99%), speci-
ﬁcity was 64% (95% CI: 35–92%), PPV was 93% (95% CI:
86–100%), and NPV was 58% (95% CI: 30–86%).
Hepatic Resection
To increase the volume of future remnant liver, preop-
erative portal vein embolization was performed in 14
patients (12%). Major hepatectomy was performed in 62
patients (52%), and any form of intraoperative vascular
occlusion was needed in 96 patients (81%). Hepatic
resection was both macroscopically and microscopically
complete in 71 patients (60%) (Table 2). One patient (1%)
died at the 19
th postoperative day due to septic shock with
multi-organ failure. Postoperative morbidity was 36% (51
complications: Clavien grade I/II, N = 42; grade III/IV,
N = 9).
27 Adjuvant chemotherapy was administered in the
majority (88%) of patients.
Long-Term Outcome
After a mean follow-up of 34 months (45 months for
surviving patients), 20 patients (17%) were alive and dis-
ease free, 18 (15%) were alive with disease recurrence, and
81 (68%) had died. Disease recurrence was diagnosed in 99
patients (83%). Repeat hepatectomy for intrahepatic
recurrence was performed in 42% of patients, and 26
patients (22%) underwent resection of an extrahepatic
recurrence.
300
250
200
150
50
100
165 ± 61
227.3
24.5
Mean CEA
Level (ng/ml)
a
p = 0.009
18 ± 21
Mean Period before Hepatectomy (Days)
300
250
200
150
50
100
176 ± 62
194.1
109.9
Mean CEA
Level (ng/ml)
b
p = 0.22
31 ± 35
Mean Period before Hepatectomy (Days)
800
600
400
200
164 ± 59
109.0
438.2
Mean CEA
Level (ng/ml)
c
p = 0.23
26 ± 28
Mean Period before Hepatectomy (Days)
FIG. 2 Change of mean CEA level measured before and after last
preoperative chemotherapy line in patients in whom radiological a
response (N = 68), b stabilization (N = 26), or c progression
(N = 19) of colorectal liver metastases was observed
TABLE 3 Change of preoperative tumor marker levels (cutoff 20%)
compared with clinical response at CT imaging after chemotherapy
Clinical response at CT
b
Response Stabilization Progression Total
Change from preoperative CEA level
a
Response 61 13 1 75 (66%)
Stabilization 3 11 0 14 (12%)
Progression 4 2 18 24 (21%)
Total 68 (60%) 26 (23%) 19 (17%) 113 (100%)
Change from preoperative CA19.9 level
a
Response 38 9 1 48 (70%)
Stabilization 1 4 3 8 (12%)
Progression 0 5 7 12 (18%)
Total 39 (57%) 18 (26%) 11 (16%) 68 (100%)
CT computed tomography, CEA carcinoembryonic antigen, CA car-
bohydrate antigen
a Cutoff point 20%
b According to RECIST criteria
22
1014 R. J. de Haas et al.Overall Survival (OS) Considering the impact of CEA
evolution on OS, 3- and 5-year OS were 44% and 28%
if patients showed a response of CEA level after
chemotherapy, 37% and 28% in case of stabilization, and
41% and 14% if CEA level had increased more than 20%,
respectively (P = 0.65) (Fig. 4a). Median OS was
33 months in each group.
For CA19.9, 3- and 5-year OS were 55% and 36% in
case of response, 40% and 0% when stabilized, and 0% and
0% when CA19.9 level had increased more than 20%
(P = 0.003) (Fig. 4b). Median OS was 40 months in the
response group, 31 months in the stabilization group, and
22 months in case of progression of CA19.9 levels.
When CLM showed a radiological response following
preoperative chemotherapy, 3- and 5-year OS were 42%
and 29%, respectively, compared with 46% and 28% if
lesions were stabilized, and 36% and 7% if progression of
CLM at CT imaging was observed (P = 0.23; median OS
of 34, 32, and 30 months, respectively) (Fig. 4c).
Progression-Free Survival (PFS) Median PFS was
9 months if CEA level responded after chemotherapy,
compared with 7 months in both stabilization and
progression groups (P = 0.17) (Fig. 4d).
Progression-free survival was signiﬁcantly inﬂuenced by
CA19.9 evolution, as none of the progressing patients was
recurrence free after 3 years, compared with 16% and 14%
of patients whose CA19.9 level showed response or sta-
bilization, respectively (P = 0.04; median PFS was
10 months in the response group versus 7 months for both
stabilization and progression groups) (Fig. 4e).
Finally, median PFS in case of radiological progression
tended to be lower than that observed after radiological
response or stabilization (7 months versus 9 months and
9 months, respectively; P = 0.06) (Fig. 4f).
Prognostic Factors of Overall Survival
On univariate analysis, study variables that were asso-
ciated with poor OS were synchronous CLM, C4 CLM at
diagnosis, diameter of largest metastasis C35 mm, bilat-
eral CLM, initial unresectability, and progression of
CA19.9 level after preoperative chemotherapy (Table 4).
After introducing all factors with univariate P B 0.10 in
a Cox proportional hazard model, three factors were
identiﬁed as independent predictors of poor OS: C4 CLM
at diagnosis, largest metastasis diameter C35 mm, and
radiological (but not biological) progression of CLM fol-
lowing preoperative chemotherapy (Table 4).
Prognostic Factors of Progression-Free Survival
On univariate analysis, nine factors were identiﬁed
which signiﬁcantly inﬂuenced PFS: female gender, syn-
chronous CLM, C3 CLM at diagnosis, bilateral CLM, type
of last preoperative chemotherapy, radiological response
14,000
12,000
10,000
8,000
4,000
2,000
6,000
163 ± 67
7678.3
260.9
Mean CA19.9
Level (U/ml)
a
p = 0.21
17 ± 22
Mean Period before Hepatectomy (Days)
600
500
400
300
100
200
175 ± 68
375.9 358.4
p = 0.86
42 ± 41
Mean Period before Hepatectomy (Days)
1800
1500
1200
900
300
600
160 ± 56
314.1
1132.8
p = 0.28
46 ± 52
Mean Period before Hepatectomy (Days)
Mean CA19.9
Level (U/ml)
b
Mean CA19.9
Level (U/ml)
c
FIG. 3 Change of mean CA19.9 level measured before and after last
preoperative chemotherapy line in patients in whom radiological. a
response (N = 39), b stabilization (N = 18), or c progression
(N = 11) of colorectal liver metastases was observed
Tumor Marker Evolution in CLM Patients 1015following chemotherapy, biological response of CA19.9
level after chemotherapy, administration of adjuvant che-
motherapy, and surgical margin status after hepatectomy
(Table 5).
On multivariate analysis, female gender, C3 CLM at
diagnosis, and progression of CA19.9 level after chemo-
therapy, but not radiological progression, were independent
predictors of decreased PFS (Table 5).
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Overall Survival
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FIG. 4 Impact of change of CEA level (a and d) and CA19.9 level
(b and e) and radiological response (c and f) after preoperative
chemotherapy on overall survival (a–c) and progression-free survival
(d–f) (a cutoff point of 20% was used to deﬁne biological response,
stabilization, and progression; radiological response was determined
according to RECIST criteria
22)
1016 R. J. de Haas et al.TABLE 4 Univariate and multivariate analysis of overall survival
Variable N 5-Year OS (%) UV P MV
a P HR (95% CI)
All patients 119 26
Patient factors
Gender
Male 79 23 0.12 – –
Female 40 30
Age at hepatectomy
\60 years 46 21 0.49 – –
C60 years 73 29
Primary malignancy
Location
Colon 95 25 0.73 – –
Rectum 24 29
T classiﬁcation
1–2 9 22 0.24 – –
3–4 74 24
N classiﬁcation
0 33 25 0.77 – –
1–2 52 18
CLM at diagnosis
Timing of diagnosis
b
Synchronous 41 14 0.009 NS –
Metachronous 78 33
No. of CLM
\47 8 3 2 0.002 \0.001 2.6 (1.6–4.3)
C43 7 1 7
Max. size of CLM
\35 mm 50 34 0.005 0.002 2.2 (1.3–3.7)
C35 mm 58 16
Distribution
Unilateral 61 35 0.004 NS –
Bilateral 57 16
Initial resectability
Yes 64 40 0.01 NS –
No 55 15
Hepatic resection
Preoperative chemotherapy
Total no. of lines
1 87 30 0.6 – –
C23 2 1 3
Total no. of cycles
\10 72 34 0.13 – –
C10 40 7
Regimen last preoperative line
5-FU LV 32 25 0.17 – –
5-FU LV oxaliplatin 61 32
5-FU LV irinotecan 18 16
Other 8 0
Tumor Marker Evolution in CLM Patients 1017Discrepancies Between Biological and Radiological
Evolution
Of patients in whom CEA level had increased more than
20% during chemotherapy treatment (N = 24), response or
stabilization was observed at CT imaging in six patients. In
addition, of 89 patients whose CEA level showed response
or stabilization during chemotherapy, one had progression
of disease at CT imaging. All of these patients developed
disease recurrence shortly after hepatic resection (median
7 months), and three of them had died at last follow-up.
When progression of CA19.9 levels was observed dur-
ing chemotherapy (N = 12), ﬁve patients had radiological
response or stabilization. Furthermore, of 56 patients with
TABLE 4 continued
Variable N 5-Year OS (%) UV P MV
a P HR (95% CI)
Chronomodulated therapy
Yes 59 28 0.57 – –
No 60 23
Radiological response at CT scan
c
Response or stabilization 100 29 0.09 0.004 2.6 (1.3–4.9)
Progression 19 7
Biological response, CEA
d
Response or stabilization 89 28 0.36 – –
Progression 24 14
Biological response, CA19.9
d
Response or stabilization 56 33 0.002 NS –
Progression 12 0
Extent of hepatic resection
Minor (\3 segments) 57 32 0.06 NS –
Major (C3 segments) 62 20
Resection type
Anatomical 58 31 0.49 – –
Nonanatomical 26 29
Both 35 12
Vascular occlusion
Yes 97 25 0.95 – –
No 17 30
Intraoperative RBC transfusion
Yes 32 25 0.85 – –
No 60 30
Postoperative chemotherapy
Yes 105 27 0.37 – –
No 11 12
Surgical margin status
e
R0 71 28 0.16 – –
R1 43 21
R2 4 25
OS overall survival, UV univariate, MV multivariate, HR hazard ratio, CI conﬁdence interval, CLM colorectal liver metastases, NS not signiﬁcant,
5-FU 5-ﬂuorouracil, LV leucovorin, CT computed tomography, CEA carcinoembryonic antigen, CA carbohydrate antigen, RBC red blood cell
a Variables with univariate P B 0.10 were entered in the Cox regression model
b Synchronous = diagnosed before, during, or within 3 months after colorectal resection
c According to RECIST criteria
22
d Cutoff point 20%
e R0: complete surgical resection with a negative surgical margin at histopathology; R1: invaded surgical margins according to the pathologist;
R2: macroscopic tumor remnant intraoperatively
1018 R. J. de Haas et al.TABLE 5 Univariate and multivariate analysis of progression-free survival
Variable N 5-Year PFS (%) UV P MV
a P HR (95% CI)
All patients 116 9
Patient factors
Gender
Male 76 20 0.05 0.04 1.9 (1.0–3.5)
Female 40 3
Age at hepatectomy
\70 years 92 9 0.85 – –
C70 years 24 10
Primary malignancy
Location
Colon 93 9 0.44 – –
Rectum 23 10
T classiﬁcation
1–2 9 0 0.64 – –
3–4 72 9
N classiﬁcation
0 32 8 0.91 – –
1–2 51 5
CLM at diagnosis
Timing of diagnosis
b
Synchronous 39 3 0.05 NS –
Metachronous 77 13
No. of CLM
\36 2 1 8 \0.001 0.02 1.9 (1.1–3.4)
C35 0 0
Max. size of CLM
\35 mm 48 15 0.28 – –
C35 mm 57 6
Distribution
Unilateral 58 18 0.006 NS –
Bilateral 57 0
Initial resectability
Yes 63 18 0.28 – –
No 53 3
Hepatic resection
Preoperative chemotherapy
Total no. of lines
1 86 9 0.97 – –
C23 0 1 0
Total no. of cycles
\10 69 11 0.08 NS –
C10 40 4
Regimen last preoperative line
5-FU LV 31 10 0.03 NS –
5-FU LV oxaliplatin 61 12
5-FU LV irinotecan 16 6
Other 8 0
Tumor Marker Evolution in CLM Patients 1019response or stabilization of CA19.9 level during chemo-
therapy, 4 had radiological progression of disease. Again,
all of these patients recurred shortly after hepatic resection
(median 6 months), and at last follow-up seven had died of
disease progression.
DISCUSSION
As the decisional value of tumor marker evolution
during chemotherapy in patients scheduled for hepatic
resection of CLM is still unclear, we aimed to deﬁne the
TABLE 5 continued
Variable N 5-Year PFS (%) UV P MV
a P HR (95% CI)
Chronomodulated therapy
Yes 59 9 0.89 – –
No 57 10
Radiological response at CT scan
c
Response or stabilization 97 11 0.02 NS –
Progression 19 0
Biological response, CEA
d
Response or stabilization 87 10 0.07 NS –
Progression 24 0
Biological response, CA19.9
d
Response or stabilization 54 13 0.01 0.002 3.2 (1.6–6.6)
Progression 12 0
Extent of hepatic resection
Minor (\3 segments) 54 13 0.31 – –
Major (C 3 segments) 62 6
Resection type
Anatomical 57 14 0.12 – –
Nonanatomical 24 9
Both 35 0
Vascular occlusion
Yes 95 8 0.49 – –
No 17 18
Intraoperative RBC transfusion
Yes 32 6 0.90 – –
No 58 13
Postoperative chemotherapy
Yes 105 10 0.009 NS –
No 10 0
Surgical margin status
e
R0 69 13 0.04 NS –
R1 42 3
R2 4 0
PFS progression-free survival, UV univariate, MV multivariate, HR hazard ratio, CI conﬁdence interval, CLM colorectal liver metastases, NS not
signiﬁcant, 5-FU 5-ﬂuorouracil, LV leucovorin, CT computed tomography, CEA carcinoembryonic antigen, CA carbohydrate antigen, RBC red
blood cell
a Variables with univariate P B 0.10 were entered in the Cox regression model
b Synchronous = diagnosed before, during, or within 3 months after colorectal resection
c According to RECIST criteria
22
d Cutoff point 20%
e R0: complete surgical resection with a negative surgical margin at histopathology; R1: invaded surgical margins according to the pathologist;
R2: macroscopic tumor remnant intraoperatively
1020 R. J. de Haas et al.correlation between biological and radiological response
following preoperative chemotherapy as well as their
impact on long-term outcome in this particular patient
group.
In the present study, CEA evolution was found to be
highly correlated with radiological response after preop-
erative chemotherapy, with sensitivity and speciﬁcity rates
exceeding 90%. However, while radiological progression
independently predicted decreased OS, change in CEA
level after chemotherapy did not signiﬁcantly impact long-
term outcome, although a trend for decreased survival was
observed in patients with increased CEA level (5-year OS
14% versus 28%).
Sensitivity of CA19.9 evolution was comparable to that
observed for CEA, with however, a lower speciﬁcity. In
contrast to CEA evolution, progression of CA19.9 level
during chemotherapy had negative impact on both OS and
PFS. In addition, progression of CA19.9 level after che-
motherapy, but not radiological response, was an
independent predictor of poor PFS.
In several large patient series, various cutoff points of
elevated tumor marker levels before hepatectomy for CLM
have been related to worse long-term outcome.
13–17 How-
ever, little evidence exists regarding the decisional value of
biological response during chemotherapy. In only four
publications was the correlation between biological and
radiological response analyzed.
18–20,28 Ward et al. assessed
the accuracy of tumor marker evolution (CEA, CA-195,
and CA-242) in monitoring patients treated by chemo-
therapy for advanced colorectal cancer. In that study, CEA
was found to have the best predictive value in monitoring
disease course during chemotherapy, which correlated
favorably with radiological changes in 88% of patients.
20
More recently, Wang et al. reported a lower rate of
agreement between imaging studies and change in CEA
level (68%).
19 In 2006, Boppudi et al. concluded that there
existed a major lack of agreement between tumoral chan-
ges at CT imaging and changes in CEA level in patients
treated by selective internal radiation therapy (SIRT) for
unresectable CLM.
28 Finally, Iwanicki-Caron et al.
recently reported that CEA kinetics is an accurate method
to identify disease progression in patients with advanced
colorectal cancer.
18 Importantly, these studies included
only patients treated in a nonsurgical setting, with colo-
rectal metastases not only conﬁned to the liver, normal
baseline CEA levels in some of them, thereby hampering
data interpretation, and no evaluation of CA19.9 kinetics.
As the value of CEA and CA19.9 evolution still remains a
matter of debate, we decided to deﬁne both the correlation
between biological and radiological response on chemo-
therapy and their comparative impact on long-term
outcome, in a well-deﬁned population of patients with
isolated CLM who were all treated by chemotherapy
followed by hepatic resection and all of whom had elevated
baseline tumor marker levels. In this way, it was logical to
assume that tumor marker levels were only related to liver
metastases, thereby enabling us to draw reliable conclu-
sions. In addition, as more than two-thirds of our patients
were treated by modern chemotherapy regimens, and by
using the RECIST criteria, our results reﬂect current
standard of care. However, although strict inclusion criteria
were used, some variation exists in the severity of meta-
static disease and in the type of chemotherapy used within
this ‘‘surgical’’ population.
When using a cutoff point of 20% change to deﬁne
biological response after chemotherapy, biological
response correlated favorably with radiological response in
80% and 72% of patients, with kappa values of 0.62 and
0.46, when either CEA or CA19.9 was analyzed, respec-
tively. It was noteworthy that patients in whom discrepancy
existed between radiological and biological response all
recurred shortly after hepatectomy, and most of them had
died at last follow-up. Therefore, determining biological
response after chemotherapy provides important additional
information, as patients whose metastases did not progress
radiologically but who did demonstrate biological pro-
gression had similar prognosis compared with patients
whose metastases showed radiological progression.
Concerning the correlation between biological and
radiological response to chemotherapy, an important ques-
tion that arises is whether tumor marker evolution should
replace radiological evaluation. In patients with potentially
resectable CLM, CT imaging remains the gold standard in
evaluating chemotherapy results, as it enables evaluation of
technical resectability of CLM. However, radiological
evaluation should be combined in these patients with bio-
logical response, as this most accurately evaluates
chemotherapy response and thus provides the best informa-
tion regarding long-term outcome. Although we have
studied a ‘‘surgical’’ population, almost half of the patients
(46%) were initially unresectable, and might not have been
treated surgically in less specialized centers. Therefore, our
results concerning biological and radiological correlation
might also be applicable for a nonsurgical population. Thus,
the efﬁcacy of systemic chemotherapy administered in a
nonsurgical treatment setting can be adequately monitored
by determining biological response, thereby lowering the
need for imaging studies. In this way, a reduction in health
care costs could be achieved, combined with an improve-
ment in patient comfort. Whether this hypothesis is true or
not should be conﬁrmed in future studies.
In our study, CEA evolution did not signiﬁcantly
inﬂuence OS and PFS, which is in contrast with the results
reported by Iwanicki-Caron et al., Wang et al. and Boppudi
et al., since in these series decrease in CEA level was
signiﬁcantly related to better survival.
18,19,28 This could be
Tumor Marker Evolution in CLM Patients 1021related to the fact that, in some of the cited studies, patients
with normal baseline tumor marker levels were also ana-
lyzed. In contrast, in our series, progression of CA19.9
level signiﬁcantly inﬂuenced OS, and more importantly, it
independently predicted poor PFS, thereby emphasizing its
importance in estimating individual outcome. The value of
CA19.9 evolution in patients with CLM treated by preop-
erative chemotherapy has to our knowledge never been
explored, and it is noteworthy that it could be more accu-
rate than CEA. Radiological progression of CLM following
preoperative chemotherapy was found to be an independent
predictor of poor OS, which is in accordance with our
previous publication reporting a similar relationship
between radiological progression and long-term outcome.
12
In summary, the results of this study clearly show that,
in patients with CLM treated by systemic chemotherapy,
biological response (as measured by both CEA and
CA19.9) and radiological response are closely correlated.
Furthermore, CA19.9 evolution is an even better prognostic
tool than radiological response with regards to PFS. In
patients treated by systemic chemotherapy in a nonsurgical
treatment setting, biological response can decrease the
need for imaging studies. In addition, in patients with
potentially resectable CLM, although CT imaging remains
irreplaceable to determine resectability, biological response
can provide relevant complementary information con-
cerning individual outcome. In the future, our results need
to be conﬁrmed by other studies.
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